Addressing the future: combination with targeted therapies, adjuvant setting and beyond.

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Mechanisms of endocrine therapy resistance, including de novo and acquired resistance, are being elucidated.
• Aromatase inhibitors (AIs) are a standard adjuvant therapy, but resistance necessitates alternative strategies.
• Improving patient outcomes beyond current AI treatments is a significant clinical challenge.

Purpose of the Study:

• To explore potential treatment options for patients with endocrine therapy-resistant breast cancer.
• To investigate strategies for overcoming resistance to endocrine therapy.
• To review the role of targeted therapies in combination with AIs.

Main Methods:

• Review of current understanding of resistance mechanisms.
• Exploration of novel therapeutic targets and combinations.
• Analysis of ongoing clinical trials investigating targeted therapies.

Main Results:

• Emerging understanding of de novo and acquired resistance pathways.
• Identification of targeted therapies as potential alternatives or adjuncts to AIs.
• Clinical trials are evaluating combinations of targeted therapies and AIs.

Conclusions:

• Simultaneous or sequential blockade of endocrine and other pathways is a promising approach.
• Targeted therapies, alone or with AIs, hold potential for improving clinical outcomes.
• Future breast cancer treatment will be shaped by ongoing clinical trial results.